Amarin loses legal fight over heart drug patent; shares sink
Amarin shares fell sharply Monday evening after a federal judge ruled that key patents covering its heart drug Vascepa were invalid.
The decision, while likely to be appealed by Amarin, is a victory for two drug makers seeking to make and sell generic versions of Vascepa.
Read Original Article: Amarin loses legal fight over heart drug patent; shares sink »
